A large brain study has identified molecular patterns associated with PTSD that differ from those seen in people without a psychiatric diagnosis and from those linked to major depressive disorder. The research examined epigenetic changes, chemical modifications that influence how genes are used without altering the DNA sequence itself. One of these processes, DNA methylation, can reduce or block gene activity and is considered a key mechanism through which experience and environment may shape brain function.
Published in Cell Reports, the study analysed donated postmortem brain tissue from 302 people: 101 with a diagnosis of post-traumatic stress disorder, 101 with major depressive disorder and 100 without a diagnosed psychiatric condition. The researchers focused on three regions central to cognition, emotion and memory: the prefrontal cortex, the amygdala and the hippocampus. Medical records were used to establish the clinical background of the donors.
The clearest PTSD-associated methylation differences appeared in the prefrontal cortex, a region involved in planning, decision-making and other higher cognitive functions. In contrast, major depressive disorder showed a more prominent methylation signal in the amygdala, a brain structure central to emotional processing. The depression-related changes also tended to affect similar sets of genes across different brain regions, while the PTSD patterns were less uniform and appeared to vary with factors including sex, ethnicity and age at the time of trauma exposure.
Frances Champagne of the University of Texas at Austin, a co-author of the study, said the findings may help explain how brains affected by PTSD differ from those without the condition. The work adds to a growing field that studies mental health through biological markers rather than symptoms alone. Seyma Katrinli of the Emory University School of Medicine, who was not involved, described the dataset as a useful resource for future research into whether measurable changes in blood could reflect molecular changes in the brain.
The findings do not provide a diagnostic test for PTSD and cannot show whether the methylation differences are a cause, consequence or associated feature of the disorder. The study also relied on postmortem tissue and medical records rather than direct assessment, and it did not account for substance use, which can also influence DNA methylation. Even so, the research gives scientists a more detailed map for investigating how trauma, biology and brain function intersect, and which variables may shape the molecular profile of PTSD over time.





